DE60035693T2 - Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten - Google Patents

Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten Download PDF

Info

Publication number
DE60035693T2
DE60035693T2 DE60035693T DE60035693T DE60035693T2 DE 60035693 T2 DE60035693 T2 DE 60035693T2 DE 60035693 T DE60035693 T DE 60035693T DE 60035693 T DE60035693 T DE 60035693T DE 60035693 T2 DE60035693 T2 DE 60035693T2
Authority
DE
Germany
Prior art keywords
polypeptide
acid sequence
antibody
amino acid
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035693T
Other languages
German (de)
English (en)
Other versions
DE60035693D1 (de
Inventor
Avi J. San Mateo Ashkenazi
Kevin P. Darnestown Baker
Sherman Alameda FONG
Audrey San Francisco Goddard
Paul J. Burlingame Godowski
Austin L. Belmont Gurney
Kenneth J. San Francisco Hillan
Melanie R. Burlingame MARK
Scot A. San Carlos Marsters
Robert M. El Cerrito Pitti
Daniel Orinda TUMAS
Colin K. Moraga Watanabe
William I. Hillsborough Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60035693D1 publication Critical patent/DE60035693D1/de
Publication of DE60035693T2 publication Critical patent/DE60035693T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
DE60035693T 1999-07-20 2000-03-15 Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten Expired - Lifetime DE60035693T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14475899P 1999-07-20 1999-07-20
US144758P 1999-07-20
PCT/US2000/006884 WO2001005972A1 (en) 1999-07-20 2000-03-15 Compositions and methods for the treatment of immune related diseases

Publications (2)

Publication Number Publication Date
DE60035693D1 DE60035693D1 (de) 2007-09-06
DE60035693T2 true DE60035693T2 (de) 2008-05-15

Family

ID=22510005

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035693T Expired - Lifetime DE60035693T2 (de) 1999-07-20 2000-03-15 Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten

Country Status (8)

Country Link
EP (1) EP1198568B1 (enExample)
JP (3) JP2003505350A (enExample)
AT (1) ATE368110T1 (enExample)
AU (1) AU4011300A (enExample)
CA (1) CA2375458A1 (enExample)
DE (1) DE60035693T2 (enExample)
ES (1) ES2291198T3 (enExample)
WO (1) WO2001005972A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US7589172B2 (en) 1999-07-20 2009-09-15 Genentech, Inc. PRO256 polypeptides
EP1239050A4 (en) * 1999-12-09 2004-07-21 Sankyo Co METHOD FOR TESTING CURATIVE OR PREVENTIVE AGENT OF HYPERLIPEMIA
US6800604B2 (en) * 2000-02-11 2004-10-05 Genentech, Inc. Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor
WO2003009865A1 (en) * 2001-07-25 2003-02-06 Genset S.A. Agonists and antagonists of energen for use in the treatment of metabolic disorders
WO2003049758A1 (en) * 2001-12-13 2003-06-19 Genset S.A. Emergen agonists and antagonists for use in the treatment of metabolic disorders
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP1744620A2 (en) * 2004-05-12 2007-01-24 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
RU2702108C2 (ru) 2013-07-16 2019-10-04 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
MY186016A (en) 2015-09-25 2021-06-14 Genentech Inc Anti-tigit antibodies and methods of use
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037638A2 (en) * 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
DE69631500T2 (de) * 1995-07-24 2004-12-02 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
US5874230A (en) * 1996-07-10 1999-02-23 Tularik, Inc. Assays using TRAF2-associated protein kinase polypeptides
AU4268097A (en) * 1996-09-12 1998-04-02 Human Genome Sciences, Inc. Chemokine alpha-4
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
WO1998025959A2 (en) * 1996-12-11 1998-06-18 Chiron Corporation Secreted human proteins
WO1999058660A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) * 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
US6171790B1 (en) * 1998-05-01 2001-01-09 Incyte Pharmaceuticals, Inc. Human protease associated proteins
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1161536A1 (en) * 1998-11-17 2001-12-12 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
JP2007222001A (ja) * 1998-11-17 2007-09-06 Sagami Chem Res Center 疎水性ドメインを有するヒトタンパク質及びそれをコードするｄｎａ
CA2347835A1 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
JP2000325087A (ja) * 1999-05-21 2000-11-28 Otsuka Pharmaceut Co Ltd Ｔｓａ２３０６遺伝子

Also Published As

Publication number Publication date
AU4011300A (en) 2001-02-05
ATE368110T1 (de) 2007-08-15
JP2003189880A (ja) 2003-07-08
CA2375458A1 (en) 2001-01-25
ES2291198T3 (es) 2008-03-01
JP2003180381A (ja) 2003-07-02
JP2003505350A (ja) 2003-02-12
DE60035693D1 (de) 2007-09-06
EP1198568B1 (en) 2007-07-25
EP1198568A1 (en) 2002-04-24
WO2001005972A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
DE69935085T2 (de) Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums
JP5401001B2 (ja) 免疫関連疾患の治療のための新規組成物と方法
DE60028054T2 (de) Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit
JP2010115195A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2005535290A (ja) 免疫関連疾患の治療のための組成物と方法
JP2010162016A (ja) 乾癬の治療のための新規組成物と方法
DE60035693T2 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
JP2010088434A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006515167A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2013240329A (ja) 全身性エリテマトーデスの治療のための組成物と方法
DE69839430T2 (de) Mit A33 verwandte Antigene und deren pharmezeutische Verwendung
DE60120500T2 (de) In Knorpelgeweben stark exprimiertes Gen
JP2011177176A (ja) 乾癬の治療のための新規組成物と方法
JP2013051961A (ja) 免疫関連疾患の治療のための新規組成物と方法
US20090017014A1 (en) Compositions and methods for the treatment of immune related diseases
JP2008301810A (ja) 免疫関連疾患を治療するための組成物及び方法
DE60130804T2 (de) Antagonistischer antikörper gegen pro842
DE69932342T2 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
JP2006515748A (ja) リウマチ様関節炎の治療のための組成物と方法
DE69920062T2 (de) Protein das die Ueberlebensrate der Stäbchen-Photorezeptoren erhöht und Nukleinsäure die dafür kodiert.
DE69932644T2 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
JP3988821B2 (ja) 免疫関連疾患を治療するための組成物及び方法
DE69932266T2 (de) Sekretiertes und transmembranes Polypeptid und dafür kodierende Nukleinsäure
DE69926415T2 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
DE60034036T2 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums

Legal Events

Date Code Title Description
8364 No opposition during term of opposition